Alpha 2.0
Login Register
» Authors » Monica Godfrey

Monica Godfrey

Explore the profile of Monica Godfrey including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 15
Citations 438
Followers 0
Related Specialties
General Medicine
Science
Allergy & Immunology
Top 10 Co-Authors
Megan Wallace
Oliver Brooks
Sara E Oliver
H Keipp Talbot
Matthew F Daley
Katherine E Fleming-Dutra
Danielle L Moulia
Grace M Lee
Beth P Bell
Ruth Link-Gelles
Published In
MMWR Morb Mortal Wkly Rep
PLoS One
Vaccine
Affiliations
Soon will be listed here.
Recent Articles
1.
Use of COVID-19 Vaccines for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024-2025
Panagiotakopoulos L, Moulia D, Godfrey M, Link-Gelles R, Roper L, Havers F, et al.
MMWR Morb Mortal Wkly Rep . 2024 Sep; 73(37):819-824. PMID: 39298394
COVID-19 vaccination provides additional protection against severe COVID-19-associated illness and death. Since September 2023, 2023-2024 Formula monovalent XBB.1-strain COVID-19 vaccines have been recommended for use in the United States for...
2.
Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2024
Britton A, Roper L, Kotton C, Hutton D, Fleming-Dutra K, Godfrey M, et al.
MMWR Morb Mortal Wkly Rep . 2024 Aug; 73(32):696-702. PMID: 39146277
Respiratory syncytial virus (RSV) is a major cause of respiratory illness and hospitalization in older adults during fall and winter in the United States. The 2023-2024 RSV season was the...
3.
Use of an Additional Updated 2023-2024 COVID-19 Vaccine Dose for Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024
Panagiotakopoulos L, Godfrey M, Moulia D, Link-Gelles R, Taylor C, Chatham-Stephens K, et al.
MMWR Morb Mortal Wkly Rep . 2024 Apr; 73(16):377-381. PMID: 38662708
COVID-19 remains an important public health threat, despite overall decreases in COVID-19-related severe disease since the start of the COVID-19 pandemic. COVID-19-associated hospitalization rates remain higher among adults aged ≥65...
4.
Development of COVID-19 vaccine policy - United States, 2020-2023
Oliver S, Wallace M, Twentyman E, Moulia D, Godfrey M, Link-Gelles R, et al.
Vaccine . 2023 Dec; 42 Suppl 3:125512. PMID: 38158297
COVID-19 vaccines represent a great scientific and public health achievement in the face of overwhelming pressures from a global pandemic, preventing millions of hospitalizations and deaths due to COVID-19 vaccines...
5.
Use of Updated COVID-19 Vaccines 2023-2024 Formula for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices - United States, September 2023
Regan J, Moulia D, Link-Gelles R, Godfrey M, Mak J, Najdowski M, et al.
MMWR Morb Mortal Wkly Rep . 2023 Oct; 72(42):1140-1146. PMID: 37856366
COVID-19 vaccines protect against severe COVID-19-associated outcomes, including hospitalization and death. As SARS-CoV-2 has evolved, and waning vaccine effectiveness has been noted, vaccine formulations and policies have been updated to...
6.
Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices -...
Fleming-Dutra K, Jones J, Roper L, Prill M, Ortega-Sanchez I, Moulia D, et al.
MMWR Morb Mortal Wkly Rep . 2023 Oct; 72(41):1115-1122. PMID: 37824423
Respiratory syncytial virus (RSV) is the leading cause of hospitalization among U.S. infants. Nirsevimab (Bevfortus, Sanofi and AstraZeneca) is recommended to prevent RSV-associated lower respiratory tract infection (LRTI) in infants....
7.
Interim Recommendations for Use of Bivalent mRNA COVID-19 Vaccines for Persons Aged ≥6 Months - United States, April 2023
Moulia D, Wallace M, Roper L, Godfrey M, Rosenblum H, Link-Gelles R, et al.
MMWR Morb Mortal Wkly Rep . 2023 Jun; 72(24):657-662. PMID: 37319020
Throughout the national public health emergency declared in response to the COVID-19 pandemic, CDC, guided by the Advisory Committee on Immunization Practices (ACIP), has offered evidence-based recommendations for the use...
8.
Effectiveness of Pfizer-BioNTech COVID-19 vaccine as evidence for policy action: A rapid systematic review and meta-analysis of non-randomized studies
Wallace M, Collins J, Moline H, Plumb I, Godfrey M, Morgan R, et al.
PLoS One . 2022 Dec; 17(12):e0278624. PMID: 36473010
In December 2020, an interim recommendation for the use of Pfizer-BioNTech COVID-19 vaccine in persons aged ≥16 years was made under Food and Drug Administration's Emergency Use Authorization. In preparation...
9.
Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines - United States, October 2022
Rosenblum H, Wallace M, Godfrey M, Roper L, Hall E, Fleming-Dutra K, et al.
MMWR Morb Mortal Wkly Rep . 2022 Nov; 71(45):1436-1441. PMID: 36355612
Four COVID-19 vaccines are currently approved for primary series vaccination in the United States under a Biologics License Application or authorized under an emergency use authorization (EUA) by the Food...
10.
Interim Recommendation of the Advisory Committee on Immunization Practices for Use of the Novavax COVID-19 Vaccine in Persons Aged ≥18 years - United States, July 2022
Twentyman E, Wallace M, Roper L, Anderson T, Rubis A, Fleming-Dutra K, et al.
MMWR Morb Mortal Wkly Rep . 2022 Aug; 71(31):988-992. PMID: 35925807
The NVX-CoV2373 (Novavax) COVID-19 vaccine is a recombinant spike (rS) protein nanoparticle vaccine with Matrix-M adjuvant to protect against infection with SARS-CoV-2, the virus that causes COVID-19. On July 13,...